PPAR Agonists for the Prevention and Treatment of Lung Cancer

PPAR Research

Volumn 2017, Issue , 2017, Pages

  Lakshmi, Sowmya P ^a,b   Reddy, Aravind T ^a,b   Banno, Asoka ^a   Reddy, Raju C ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CANCER CHEMOTHERAPY; CANCER PREVENTION; LUNG CANCER; REVIEW;

EID: 85029359109     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2017/8252796     Document Type: Review

References (74)

1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, " International Journal of Cancer, vol. 136, no. 5, pp. E359-E386, 2015.
2. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2016, " CA Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7-30, 2016.
3. J. Malhotra, M. Malvezzi, E. Negri, C. La Vecchia, and P. Boffetta, "Risk factors for lung cancer worldwide, " European Respiratory Journal, vol. 48, no. 3, pp. 889-902, 2016.
4. L. Shi, L. Wang, J. Hou et al., "Targeting roles of inflammatory microenvironment in lung cancer and metastasis, " Cancer and Metastasis Reviews, vol. 34, no. 2, pp. 319-331, 2015.
5. G. P. Kalemkerian, W. Akerley, P. Bogner et al., "Small cell lung cancer, " Journal of the National Comprehensive Cancer Network, vol. 11, no. 1, pp. 78-98, 2013.
6. Y. Sekido, K. M. Fong, and J. D. Minna, "Progress in understanding the molecular pathogenesis of human lung cancer, " Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, vol. 1378, no. 1, pp. F21-F59, 1998.
7. D. S. Ettinger, D. E. Wood, W. Akerley et al., "NCCN guidelines insights: non-small cell lung cancer, version 4. 2016, " JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 3, pp. 255-264, 2016.
8. V. G. Keshamouni, S. Han, and J. Roman, "Peroxisome proliferator-activated receptors in lung cancer, " PPAR Research, vol. 2007, Article ID 90289, 10 pages, 2007.
9. P. E. Almeida, A. B. Carneiro, A. R. Silva, and P. T. Bozza, "PPAR expression and function in mycobacterial infection: roles in lipid metabolism, immunity, and bacterial killing, " PPAR Research, vol. 2012, Article ID 383829, 7 pages, 2012.
10. R. B. Clark, "The role of PPARs in inflammation and immunity, " Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388-400, 2002.
11. L. Michalik, B. Desvergne, andW. Wahli, "Peroxisome-proliferator-activated receptors and cancers: complex stories, " Nature Reviews Cancer, vol. 4, no. 1, pp. 61-70, 2004.
12. L. Michalik and W. Wahli, "PPARs mediate lipid signaling in inflammation and cancer, " PPAR Research, vol. 2008, Article ID 134059, 15 pages, 2008.
13. J. E. Ward and X. Tan, "Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease, " PPAR Research, vol. 2007, Article ID 14983, 12 pages, 2007.
14. J. M. Peters, Y. M. Shah, and F. J. Gonzalez, "The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention, " Nature Reviews Cancer, vol. 12, no. 3, pp. 181-195, 2012.
15. B. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, "An overview on biologicalmechanisms of PPARs, " Pharmacological Research, vol. 51, no. 2, pp. 85-94, 2005.
16. K. Tachibana, D. Yamasaki, K. Ishimoto, andT. Doi, "The role of PPARs in cancer, " PPAR Research, vol. 2008, Article ID 102737, 15 pages, 2008.
17. A. K. Reka, M. T. Goswami, R. Krishnapuram, T. J. Standiford, and V. G. Keshamouni, "Molecular cross-regulation between PPAR-and other signaling pathways: implications for lung cancer therapy, " Lung Cancer, vol. 72, no. 2, pp. 154-159, 2011.
18. M. Y. Li, T. W. Lee, A. P. Yim, and G. G. Chen, "Function of Ppar and its ligands in lung cancer, " Critical Reviews in Clinical Laboratory Sciences, vol. 43, no. 2, pp. 183-202, 2006.
19. V. R. Narala, R. K. Adapala, M. V. Suresh, T. G. Brock, M. Peters-Golden, and R. C. Reddy, "Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-agonist, " Journal of Biological Chemistry, vol. 285, no. 29, pp. 22067-22074, 2010.
20. R. A. Daynes and D. C. Jones, "Emerging roles of PPARs in inflammation and immunity, " Nature Reviews Immunology, vol. 2, no. 10, pp. 748-759, 2002.
21. Y. Li, J. Zhang, F. J. Schopfer et al., "Molecular recognition of nitrated fatty acids by PPAR, " Nature Structural & Molecular Biology, vol. 15, no. 8, pp. 865-867, 2008.
22. A. T. Reddy, S. P. Lakshmi, Y. Zhang, and R. C. Reddy, "Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages, "TheFASEB Journal, vol. 28, no. 12, pp. 5299-5310, 2014.
23. J. Berger and D. E. Moller, "The mechanisms of action of PPARs, " Annual Review of Medicine, vol. 53, pp. 409-435, 2002.
24. M.-Y. Li, H. Yuan, L. T. Ma et al., "Roles of peroxisome proliferator-activated receptor-and-in the development of nonsmall cell lung cancer, " American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 6, pp. 674-683, 2010.
25. T. V. Pedchenko, A. L. Gonzalez, D. Wang, R. N. DuBois, and P. P. Massion, "Peroxisome proliferator-activated receptor / expression and activation in lung cancer, " American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 6, pp. 689-696, 2008.
26. K.-I. Inoue, Y. Kawahito, Y. Tsubouchi et al., "Expression of peroxisome proliferator-activated receptor (PPAR)-in human lung cancer, " Anticancer Research, vol. 21, no. 4A, pp. 2471-2476, 2001.
27. I. Issemann and S. Green, "Activation of amember of the steroid hormone receptor superfamily by peroxisome proliferators, " Nature, vol. 347, no. 6294, pp. 645-650, 1990.
28. J. M. Peters, R. C. Cattley, and F. J. Gonzalez, "Role of PPAR in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferatorWy-14, 643, " Carcinogenesis, vol. 18, no. 11, pp. 2029-2033, 1997.
29. A. Kaipainen, M. W. Kieran, S. Huang et al., "PPAR deficiency in inflammatory cells suppresses tumor growth, " PLOS ONE, vol. 2, no. 2, article e260, 2007.
30. D. Panigrahy, A. Kaipainen, S. Huang et al., "PPAR agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 3, pp. 985-990, 2008.
31. A. Pozzi, M. R. Ibanez, A. E. Gatica et al., "Peroxisomal proliferator-activated receptor-dependent inhibition of endothelial cell proliferation and tumorigenesis, " Journal of Biological Chemistry, vol. 282, no. 24, pp. 17685-17695, 2007.
32. N. Skrypnyk, X. Chen, W. Hu et al., "PPAR activation can help prevent and treat non-small cell lung cancer, " Cancer Research, vol. 74, no. 2, pp. 621-631, 2014.
33. T. Kuno, K. Hata, M. Takamatsu et al., "The peroxisome proliferator-activated receptor (PPAR) agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice, " International Journal of Molecular Sciences, vol. 15, no. 5, pp. 9160-9172, 2014.
34. A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, "The role of peroxisome proliferator-activated receptor-/ in epithelial cell growth and differentiation, " Cellular Signalling, vol. 18, no. 1, pp. 9-20, 2006.
35. L. Yang, H. Zhang, Z.-G. Zhou, H. Yan, G. Adell, and X.-F. Sun, "Biological function and prognostic significance of peroxisome proliferator-activated receptor in rectal cancer, " Clinical Cancer Research, vol. 17, no. 11, pp. 3760-3770, 2011.
36. B. H. Park, B. Vogelstein, and K. W. Kinzler, "Genetic disruption of PPAR decreases the tumorigenicity of human colon cancer cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2598-2603, 2001.
37. K. Fukumoto, Y. Yano, N. Virgona et al., "Peroxisome proliferator-activated receptor as a molecular target to regulate lungcancer cell growth, " FEBS Letters, vol. 579, no. 17, pp. 3829-3836, 2005.
38. R. L. Keith, Y. E. Miller, T. M. Hudish et al., "Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice, " Cancer Research, vol. 64, no. 16, pp. 5897-5904, 2004.
39. R. L. Keith, Y. E. Miller, Y. Hoshikawa et al., "Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer, " Cancer Research, vol. 62, no. 3, pp. 734-740, 2002.
40. S. Müller-Brüsselbach, S. Ebrahimsade, J. Jäkel et al., "Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene, " International Journal of Oncology, vol. 31, no. 3, pp. 607-611, 2007.
41. Z. Haskova, B. Hoang, G. Luo et al., "Modulation of LPSinduced pulmonary neutrophil infiltration and cytokine production by the selective PPAR/ ligand GW0742, " Inflammation Research, vol. 57, no. 7, pp. 314-321, 2008.
42. R. Di Paola, C. Crisafulli, E. Mazzon et al., "GW0742, a highaffinity PPAR-/ agonist, inhibits acute lung injury in mice, " Shock, vol. 33, no. 4, pp. 426-435, 2010.
43. D. R. Brenner, D. Scherer, K. Muir et al., "A review of the application of inflammatory biomarkers in epidemiologic cancer research, " Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 9, pp. 1729-1751, 2014.
44. S. Müller-Brüsselbach, M. Kömhoff, M. Rieck et al., "Deregulation of tumor angiogenesis and blockade of tumor growth in PPAR-deficient mice, "EMBOJournal, vol. 26, no. 15, pp. 3686-3698, 2007.
45. P. He, M. G. Borland, B. Zhu et al., "Effect of ligand activation of peroxisome proliferator-activated receptor-/ (PPAR/) in human lung cancer cell lines, " Toxicology, vol. 254, no. 1-2, pp. 112-117, 2008.
46. P. S. Palkar, M. G. Borland, S. Naruhn et al., "Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-/ antagonist GSK3787, " Molecular Pharmacology, vol. 78, no. 3, pp. 419-430, 2010.
47. T.-H. Chang and E. Szabo, "Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor in non-small cell lung cancer, " Cancer Research, vol. 60, no. 4, pp. 1129-1138, 2000.
48. Y. Tsubouchi, H. Sano, Y. Kawahito et al., "Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-agonists through induction of apoptosis, " Biochemical and Biophysical Research Communications, vol. 270, no. 2, pp. 400-405, 2000.
49. W. Guo and F. G. Giancotti, "Integrin signalling during tumour progression, " Nature Reviews Molecular Cell Biology, vol. 5, no. 10, pp. 816-826, 2004.
50. G. Bergers and L. E. Benjamin, "Tumorigenesis and the angiogenic switch, " Nature Reviews Cancer, vol. 3, no. 6, pp. 401-410, 2003.
51. E. S. White, S. R. B. Strom, N. L. Wys, and D. A. Arenberg, "Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity, " Journal of Immunology, vol. 166, no. 12, pp. 7549-7555, 2001.
52. H. Paz, N. Pathak, and J. Yang, "Invading one step at a time: The role of invadopodia in tumor metastasis, " Oncogene, vol. 33, no. 33, pp. 4193-4202, 2014.
53. M. Ricote, J. T. Huang, J. S. Welch, andC. K. Glass, "The peroxisome proliferator-activated receptor (PPAR) as a regulator of monocyte/macrophage function, " Journal of Leukocyte Biology, vol. 66, no. 5, pp. 733-739, 1999.
54. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, "The peroxisome proliferator-activated receptor-is a negative regulator of macrophage activation, " Nature, vol. 391, no. 6662, pp. 79-82, 1998.
55. C. Jiang, A. T. Ting, and B. Seed, "PPAR-agonists inhibit production of monocyte inflammatory cytokines, " Nature, vol. 391, no. 6662, pp. 82-86, 1998.
56. J. A. Van Ginderachter, K. Movahedi, J. Van Den Bossche, and P. De Baetselier, "Macrophages, PPARs, and cancer, " PPAR Research, vol. 2008, Article ID 169414, 11 pages, 2008.
57. M. V. Schmidt, B. Brüne, and A. Von Knethen, "The nuclear hormone receptor PPAR as a therapeutic target in major diseases, " TheScientificWorldJournal, vol. 10, pp. 2181-2197, 2010.
58. H. A. Burgess, L. E. Daugherty, T. H. Thatcher et al., "PPAR agonists inhibit TGF-induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis, " American Journal of Physiology-Lung Cellular andMolecular Physiology, vol. 288, no. 6, pp. L1146-L1153, 2005.
59. J. E. Milam, V. G. Keshamouni, S. H. Phan et al., "PPAR-agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis, " American Journal of Physiology-Lung Cellular andMolecular Physiology, vol. 294, no. 5, pp. L891-L901, 2008.
60. M. Shimoda, K. T. Mellody, and A. Orimo, "Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression, " Seminars in Cell and Developmental Biology, vol. 21, no. 1, pp. 19-25, 2010.
61. M. Fang, J. Yuan, C. Peng, andY. Li, "Collagenasadouble-edged sword in tumor progression, " Tumor Biology, vol. 35, no. 4, pp. 2871-2882, 2014.
62. T. J. Standiford, V. C. Keshamouni, and R. C. Reddy, "Peroxisome proliferator-activated receptor-as a regulator of lung inflammation and repair, " Proceedings of the AmericanThoracic Society, vol. 2, no. 3, pp. 226-231, 2005.
63. A. T. Reddy, S. P. Lakshmi, J. M. Kleinhenz, R. L. Sutliff, C. M. Hart, and R. C. Reddy, "Endothelial cell peroxisome proliferator-activated receptor reduces endotoxemic pulmonary inflammation and injury, " The Journal of Immunology, vol. 189, no. 11, pp. 5411-5420, 2012.
64. F. Ondrey, "Peroxisome proliferator-activated receptor pathway targeting in carcinogenesis: implications for chemoprevention, " Clinical Cancer Research, vol. 15, no. 1, pp. 2-8, 2009.
65. V. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., "Peroxisomeproliferator-activated receptor-activation inhibits tumor progression in non-small-cell lung cancer, " Oncogene, vol. 23, no. 1, pp. 100-108, 2004.
66. M. Wick, G. Hurteau, C. Dessev et al., "Peroxisome proliferator-activated receptor-is a target of nonsteroidal antiinflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth, "Molecular Pharmacology, vol. 62, no. 5, pp. 1207-1214, 2002.
67. Y. Wang, M. James, W. Wen et al., "Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice, " Molecular Cancer Therapeutics, vol. 9, no. 11, pp. 3074-3082, 2010.
68. R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., "Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes, " Journal of Clinical Oncology, vol. 25, no. 12, pp. 1476-1481, 2007.
69. G. D. Girnun, E. Naseri, S. B. Vafai et al., "Synergy between PPAR ligands and platinum-based drugs in cancer, " Cancer Cell, vol. 11, no. 5, pp. 395-406, 2007.
70. R. C. Reddy, A. Srirangam, K. Reddy et al., "Chemotherapeutic drugs induce PPAR-expression and show sequence-specific synergy with PPAR-ligands in inhibition of non-small cell lung cancer, " Neoplasia, vol. 10, no. 6, pp. 597-603, 2008.
71. S. Y. Lee, G. Y. Hur, K. H. Jung et al., "PPAR-agonist increase gefitinib's antitumor activity through PTEN expression, " Lung Cancer, vol. 51, no. 3, pp. 297-301, 2006.
72. C.-J. Yao, G.-M. Lai, C.-F. Chan, A.-L. Cheng, Y.-Y. Yang, andS.-E. Chuang, "Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone, " International Journal of Cancer, vol. 118, no. 3, pp. 773-779, 2006.
73. K. Still, P. Grabowski, I. Mackie, M. Perry, and N. Bishop, "The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo, " Calcified Tissue International, vol. 83, no. 4, pp. 285-292, 2008.
74. A. Tenenbaum, V. Boyko, E. Z. Fisman et al., "Does the lipidlowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease" Cardiovascular Diabetology, vol. 7, article 18, 2008.